The Coming of Age of Biosimilars: A Personal Perspective
Biosimilars have come of age over the past 17 years, with 84 approvals in the EU and 35 in the US, representing almost 90% of the world market. While the acceptance of biosimilars in the US is catching up with that in the EU, the cost benefits remain elusive due to the high development barrier and c...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-04-01
|
| Series: | Biologics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-8449/2/2/9 |